Amneal announces complete response resubmission for ipx203 new drug application

Bridgewater, n.j., feb. 08, 2024 (globe newswire) -- amneal pharmaceuticals, inc. (nasdaq: amrx) (“amneal” or the “company”) today announced that it has provided a complete response resubmission to the u.s. food and drug administration (fda) for ipx203, a novel, oral formulation of carbidopa/levodopa (cd/ld) extended-release capsules for the treatment of parkinson's disease (pd).
AMRX Ratings Summary
AMRX Quant Ranking